Oncology Division
Alphabetical list (active faculty):   
Ravi Vij

Ravi Vij, MD, MBA


Department of Medicine

Oncology Division

Bone Marrow Transplantation & Leukemia

Research Interests

  • Stem cell transplantation for hematologic malignancy
  • Multiple myeloma
  • Acute myeloid leukemia/myelodysplastic syndromes


  • 314-454-8304 (office)
  • 314-454-7551 (fax)
  • Division of Oncology
    Mail Stop 8007-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)


My area of academic pursuit is the treatment of hematologic malignancies and hematopoietic stem cell transplantation. I serve on the Core Transplant, Myeloma and Leukemia Committees of the CALGB, the Myeloma Committee of the BMT Clinical Trials Network (CTN) and the Multiple Myeloma Cancer immunotherapy Guideline panel of the Society for Immunotherapy of Cancer. I also serve on the Project Review Committee and Steering Committee of the CoMMpass Study of the Multiple Research Consortium (MMRC). I have served on the Education Committee of the American Society of Clinical Oncology and and the American Society of Hematology Scientific Committee on Plasma Cell Dyscrasias. I have served as principal investigator on several national and institutional clinical trials looking at strategies to improve the outcome of patients with multiple myeloma, acute myeloid leukemia and myelodysplastic syndromes and played a role in the development drugs approved for Multiple Myeloma including Carfilzomib, Pomalidomide, Elotuzumab Selinexor and Isatuximab.

As Chair of the Development Program Advisory Panel for the Center for Multiple Myeloma Nanotechnology at Washington University and as the Principal Investigator for the Multiple Myeloma Tissue Banking initiative, I am working closely with basic scientists both within and outside the institution to study the genomics and biology of the disease and harness the knowledge to foster better therapeutic options including a number of personalized medicine and immunotherapy initiatives for treatment of multiple myeloma.